ID   ILKM2
AC   CVCL_A621
SY   ILKM-2
DR   CGH-DB; 9149-4
DR   Wikidata; Q54897484
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=2783335;
RX   PubMed=10936422;
RX   PubMed=11429052;
RX   PubMed=12886255;
RX   PubMed=15215163;
RX   PubMed=17229644;
RX   PubMed=20079716;
CC   Population: Japanese.
CC   Characteristics: Produces IgG kappa.
CC   Characteristics: IL6 dependent.
CC   Doubling time: 120 hours (PubMed=2783335).
CC   Omics: Variations; Array-based CGH.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 19
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=2783335; DOI=10.1084/jem.169.1.339; PMCID=PMC2189192;
RA   Shimizu S., Yoshioka R., Hirose Y., Sugai S., Tachibana J., Konda S.;
RT   "Establishment of two interleukin 6 (B cell stimulatory factor
RT   2/interferon beta 2)-dependent human bone marrow-derived myeloma cell
RT   lines.";
RL   J. Exp. Med. 169:339-344(1989).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x; PMCID=PMC5926752;
RA   Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K.,
RA   Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S.,
RA   Sonta S.-i., Nitta M., Taniwaki M., Ueda R.;
RT   "Ectopic expression of MAFB gene in human myeloma cells carrying
RT   (14;20)(q32;q11) chromosomal translocations.";
RL   Jpn. J. Cancer Res. 92:638-644(2001).
//
RX   PubMed=12886255; DOI=10.1038/sj.leu.2403026;
RA   Hayami Y., Iida S., Nakazawa N., Hanamura I., Kato M., Komatsu H.,
RA   Miura I., Dave B.J., Sanger W.G., Lim B., Taniwaki M., Ueda R.;
RT   "Inactivation of the E3/LAPTm5 gene by chromosomal rearrangement and
RT   DNA methylation in human multiple myeloma.";
RL   Leukemia 17:1650-1657(2003).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2; PMCID=PMC1618545;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=17229644; DOI=10.3324/haematol.10300;
RA   Sanda T., Iida S., Kayukawa S., Ueda R.;
RT   "Induction of class II major histocompatibility complex expression in
RT   human multiple myeloma cells by retinoid.";
RL   Haematologica 92:115-120(2007).
//
RX   PubMed=20079716; DOI=10.1016/j.bbrc.2010.01.038;
RA   Iqbal M.S., Tsuyama N., Obata M., Ishikawa H.;
RT   "A novel signaling pathway associated with Lyn, PI 3-kinase and Akt
RT   supports the proliferation of myeloma cells.";
RL   Biochem. Biophys. Res. Commun. 392:415-420(2010).
//